In patients weighing ≤50 kg, the benefits of apixaban were less pronounced but still showed a trend favouring its use versus VKA (stroke/systemic embolism: HR, .80 [95% CI: .58; 1.12]; clinically relevant bleedings: HR, .87 [95% CI: .73; 1.04]; ICH: HR, .62 [95% CI: .38; 1.02]; all‐cause death: HR, .90 [95% CI: .81; 1.01]).
← all excerpts
Apixaban in patients with nonvalvular atrial fibrillation, heart failure and low body weight: A report from a global federated research dataset.
1
—
—